Ocular adverse drug reactions and the National Registry of Drug-Induced Ocular Side Effects

Insight - Journal of the American Society of Ophthalmic Registered Nurses

Volumn 29, Issue 2, 2004, Pages 7-11

  Fraunfelder, F W ^a  

^a or 97239 4197   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMIODARONE; BCR ABL PROTEIN; CETIRIZINE; ETIDRONIC ACID; HYDROXYCHLOROQUINE; IMATINIB; ISOTRETINOIN; PAMIDRONIC ACID; PHENOTHIAZINE; PHENYLEPHRINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RISEDRONIC ACID; SILDENAFIL; STEM CELL FACTOR RECEPTOR; TOPIRAMATE; ZOLEDRONIC ACID;

ACCOMMODATION; ACNE CYSTICA; ALLERGIC RHINITIS; ANISOCORIA; ARTICLE; AWARENESS; BLEPHARITIS; BLEPHAROSPASM; BLINDNESS; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COLOR VISION DEFECT; CONJUNCTIVITIS; CONTACT LENS; CORNEA DISEASE; DARK ADAPTATION; DEPRESSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DIPLOPIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EPILEPSY; EPIPHORA; EPISCLERITIS; ERECTILE DYSFUNCTION; EYE DISEASE; FATIGUE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEALTH PRACTITIONER; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HUMAN; IRIDOCYCLITIS; ISCHEMIC OPTIC NEUROPATHY; KERATOCONJUNCTIVITIS SICCA; MALIGNANT HYPERTENSION; MEIBOMIAN GLAND; MIGRAINE; MUSCLE CRAMP; MYALGIA; MYOPIA; NAUSEA; NERVE PARALYSIS; NIGHT BLINDNESS; OCULOGYRIC CRISIS; OPHTHALMOLOGY; OPTIC NERVE DISEASE; OROFACIAL DYSKINESIA; PATIENT MONITORING; PSORIASIS; PTOSIS; PUNCTATE KERATITIS; RASH; REGISTER; RETINA DISEASE; RETINA EXAMINATION; RETINA MACULOPATHY; RETROBULBAR OPTIC NEUROPATHY; RHEUMATOID ARTHRITIS; SCLERITIS; SCOTOMA; SEBACEOUS GLAND DISEASE; SKIN EDEMA; SKIN PIGMENTATION; SOMNOLENCE; STAPHYLOCOCCUS INFECTION; SUBARACHNOID HEMORRHAGE; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; VISUAL IMPAIRMENT; XEROSTOMIA;

EYE DISEASES; HUMANS; NATIONAL HEALTH PROGRAMS; PHARMACEUTICAL PREPARATIONS; REGISTRIES; UNITED STATES;

EID: 4143066067     PISSN: 1060135X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fraunfelder FT, Meyer SM. Amiodarone keratopathy. Trans Ophthalmol Soc N Z. 1984;36:33-34.
2. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol. 1998;43:360-366.
3. Arnold AC. Ischemic optic neuropathies. Ophthalmol Clin North Am. 2001;14(1):83-98.
4. Hayreh SS. Anterior ischemic optic neuropathy: trouble waiting to happen. Ophthalmology. 2000;107(3): 407-410.
5. Knox DL, Kerrison JB, Green WR. Histopathologic studies of ischemic optic neuropathy. Trans Am Ophthalmol Soc. 2000;98:203-220; discussion 221-222.
6. Lessell S. Nonarteritic anterior ischemic optic neuropathy: enigma variations. Arch Ophthalmol. 1999;117(3):386-388.
7. Newman NJ, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002;134(3):317-328.
8. Feiner LA, et al. Optic neuropathy and amiodorane therapy. Mayo Clin Proc. 1987;62(8):702-717.
9. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol. 1999;127(5):610-612.
10. Fraunfelder FT, Fraunfelder FW. Drug-Induced Ocular Side Effects. 5th ed. Woburn, MA: Butterworth-Heinemann; 2001:824.
11. Fraunfelder FW, Fraunfelder FT. Oculogyric crisis in patients taking cetirizine. Submitted to Arch Ophthalmol. 2003.
12. Onuaguluchi G. Crises in post-encephalitic parkinsonism. Brain. 1961;84:395.
13. Marmor MF, Carr RE, Easterbrook M. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109:1377-1382.
14. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin. 1999;39:49-57.
15. Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol. 1990;25:249-251.
16. Druker BJ, Sawyer CL, Kantarjian HM. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
17. Druker BJ, Talpaz M, Resta DJ. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
18. Heinrich MC, Griffith DJ, Druker BJ. Inhibition of c-kit receptor tyrosine kinase activity by STI571: targeting BCE-ABL as therapy for CML. Oncologist. 2000;96:925-932.
19. Mauro MJ, Druker BJ. STI571: targeting BCE-ABL as therapy for CML. Oncologist. 2001;6:233-238.
20. Van Oosterom AT, Judson I, Verwej J. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet. 2001;358:1421-1423.
21. Demetri G, von Mehran M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
22. Hasselbalch HC. STI571 (Gleevec), a new drug for the treatment of chronic myeloid leukemia. Ugeskr Laeger. 2002;164:2914-2917.
23. Esmaeli B, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95(4):881-887.
24. Fraunfelder FW, et al. Ocular side effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. In press. 2003.
25. Mathers WD, et al. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea. 1991;10:286-290.
26. Fraunfelder FW, Fraunfelder FT. Isotretinoin and intracranial hypertension. Ophthalmology. In press. 2003.
27. Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol. 1985;100(4):534-537.
28. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol. 1994;118(2):220-224.
29. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. 2003;135(2):219-222.
30. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular side effects. N Engl J Med. 2003;348(12):1187-1188.
31. Fraunfelder FT, Meyer SM. Systemic reactions to ophthalmic drug preparations. Med Toxicol Adverse Drug Exp. 1987;2(4):287-293.
32. Fraunfelder FT, Meyer SM. Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. Am J Ophthalmol. 1985;99(3):362-363.
33. Fraunfelder FW, Rich LF. Possible adverse effects of drugs used in refractive surgery. J Cataract Refract Surg. 2003;29(1):170-175.
34. Fraunfelder FW, Fraunfelder FT, Jensvold B. Adverse systemic effects from pledgets of topical ocular phenylephrine 10%. Am J Ophthalmol. 2002;134(4):624-625.
35. Laties AM, Fraunfelder FT. Ocular safety of Viagra (sildenafil citrate). Trans Am Ophthalmol Soc. 1999;97:115-125; discussion 125-128.
36. Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol. 2001;119(8):1210-1211.
37. Thambi L, et al. Topiramate-associated secondary angle-closure glaucoma: a case series. Arch Ophthalmol. 2002;120(8):1108.
38. Fraunfelder FW, Fraunfelder FT. Topiramate associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology. 2003;111(1):109-111.